Human trials for the indigenous, inactivated vaccine will begin across the country next month, Bharat Biotech said. The collaboration with the ICMR and the NIV was instrumental in the development of this vaccine. "Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform", said Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech.
China National Biotec Group (CNBG) said on Sunday that early human test results for a coronavirus vaccine candidate suggested it could be safe and effective, the second vaccine candidate from the firm to show encouraging results in a clinical trial.
Developed by Hyderabad-based Bharat Biotech and the Indian Council of Medical Research (ICMR), the COVAXIN candidate uses an inactivated strain of the novel coronavirus to prime the body to generate an immune response and fight off the actual virus attack.
Shots will not be able to get approval if studies only show that they lead to the development of antibodies in the bloodstream, which is not proof that the vaccine can actually prevent coronavirus infection.
China's military has approved for use within its ranks a coronavirus vaccine that has been developed by its research unit and a biotech company, which made the announcement yesterday. "The proactive support and guidance from the Central Drugs Standard Control Organisation have enabled approvals to this project". Half a dozen Indian firms are developing vaccines.
China first announced it had been permitted to test its potential Covid-19 vaccine on humans last week.
More than half of 17 candidate vaccines identified by the World Health Organization (WHO) that are in clinical evaluation involve Chinese companies or institutes.
The Ad5-nCoV is one of China's eight vaccine candidates approved for human trials at home and overseas for the respiratory disease caused by the new coronavirus. Since January, J&J has been working directly with governments and health authorities to help end this fast-moving COVID-19 pandemic.
Meanwhile, India reported over 18,000 cases on 29 June alone.
The company's efforts, part of the global race to develop a vaccine against COVID-19, comes as the pandemic continues its spread with more than 10 million cases and over 5,05,000 fatalities across the world.
The Ministry of Home Affairs has released guidelines for Unlock 2.0, which is expected to come into force till 31 July.